Skip to content

US · OPK · BIOTECHNOLOGY

OPKO Health, Inc. (OPK) intrinsic value and stock valuation

$1.57as of 2026-11-21 · Mkt cap 1.02B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

OPKO Health, Inc. DCF and intrinsic value

InvestorsCraft values OPK with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from OPK’s statements →

OPKO Health, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Miami, FL 33137 opko.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$606.9M-15.8% 5y CAGRd
20112025
Net income
-$-225.68M
20112025
Free cash flow
-$-190.82M
20112025
Total equity
$1.27B-5.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$606.9M$713.1M$863.5M$1B$1.77B
Operating income-$-218.99M-$-152.06M-$-157.02M-$-226.25M$18.8M
Net income-$-225.68M-$-53.22M-$-188.86M-$-328.4M-$-30.14M
EPSd-$-300.45K-$-76.68K-$-251.22K-$-456.71K-$-46.51K
Operating cash flow-$-178.54M-$-183.49M-$-28.2M-$-95.19M$38.3M
Capital expenditure-$-12.28M-$-25.01M-$-16.27M-$-24.58M-$-32.16M
Free cash flow-$-190.82M-$-208.5M-$-44.47M-$-119.77M$6.18M
Total assets$1.93B$2.2B$2.01B$2.17B$2.4B
Total debt$433.6M$504.4M$326.6M$305.6M$254.8M
Net debt$64.5M$72.5M$230.7M$152.4M$120.1M
Total equity$1.27B$1.37B$1.39B$1.56B$1.69B
Cash and short-term investments$369.1M$431.9M$95.9M$153.2M$134.7M
Income statement
20252024202320222021
Revenue$606.9M$713.1M$863.5M$1B$1.77B
Cost of revenue$478.8M$402.1M$545.4M$716M$1.19B
Gross profit$128.1M$311M$318.1M$288.2M$581.5M
Research and development expenses$124M$105.2M$89.6M$73.9M$76.9M
Selling, general and administrative expenses$223M$304.2M$300.6M$372.7M$468.9M
Other expenses$0.00$53.7M$85M$67.9M$17.1M
Operating expenses$347M$463.1M$475.2M$514.5M$562.8M
Cost and expenses$825.9M$865.2M$1.02B$1.23B$1.76B
Interest income$14.8M$8.43M$3.98M$1.98M$30K
Interest expense$108.5M$47.5M$13.5M$12.1M$18.9M
Depreciation and amortization$91.6M$98.2M$105.3M$108.7M$78.7M
Ebitda-$-41.3M$135.3M-$-65.52M-$-270.81M$83.6M
Operating income-$-218.99M-$-152.06M-$-157.02M-$-226.25M$18.8M
Total other income/expenses, net-$-22.41M$141.7M-$-27.41M-$-165.65M-$-33.4M
Income before tax-$-241.39M-$-10.36M-$-184.43M-$-391.9M-$-14.65M
Income tax expense-$-15.71M$42.8M$4.44M-$-63.5M$15.5M
Net income-$-225.68M-$-53.22M-$-188.86M-$-328.4M-$-30.14M
Weighted average shares outstanding$751.1M$694M$751.8M$719.1M$648.1M
Weighted average diluted shares outstanding$751.1M$694M$751.8M$719.1M$648.1M
Balance sheet
20252024202320222021
Cash and short-term investments$369.1M$431.9M$95.9M$153.2M$134.7M
Net receivables$126.1M$152.1M$130.2M$148.6M$265.6M
Inventory$65.8M$56.8M$65.7M$74.1M$86.5M
Total current assets$581.9M$662.1M$309.5M$394.5M$823M
Property, plant and equipment, net$120.9M$124.1M$143.5M$121.6M$124M
Goodwill and intangible assets$1B$1.34B$1.53B$1.61B$1.43B
Long-term investments$14.2M$54.6M$16.1M$28.1M$10.7M
Total non-current assets$1.35B$1.54B$1.7B$1.77B$1.58B
Total assets$1.93B$2.2B$2.01B$2.17B$2.4B
Accounts payable$41.1M$47.1M$69.7M$67M$82M
Short-term debt$22.9M$29.4M$43.1M$51M$28.6M
Deferred revenue$0.00$0.00$0.00$0.00$260K
Total current liabilities$146.7M$193.1M$200.1M$213.5M$330M
Long-term debt$410.7M$475.1M$283.5M$254.5M$226.2M
Deferred revenue, non-current$0.00$10K$10K$140K$210K
Total non-current liabilities$517.3M$641.7M$422.4M$392.1M$384.6M
Capital lease obligations$40.2M$67.2M$77.2M$49.5M$49.9M
Total liabilities$664M$834.8M$622.5M$605.6M$714.6M
Common stock$7.9M$7.01M$7.82M$7.81M$6.9M
Retained earnings-$-2.29B-$-2.07B-$-2.01B-$-1.82B-$-1.51B
Accumulated other comprehensive income (loss)-$-21.02M-$-56.13M-$-38.03M-$-43.32M-$-30.5M
Total equity$1.27B$1.37B$1.39B$1.56B$1.69B
Total investments$14.2M$54.6M$16.1M$28.1M$10.7M
Total debt$433.6M$504.4M$326.6M$305.6M$254.8M
Net debt$64.5M$72.5M$230.7M$152.4M$120.1M
Cash flow statement
20252024202320222021
Net income-$-225.68M-$-53.22M-$-188.86M-$-328.4M-$-30.14M
Depreciation and amortization$91.6M$98.2M$105.3M$108.7M$78.7M
Stock-based compensation$10.7M$11.1M$11.4M$18.5M$13.6M
Change in working capital-$-41.18M$32.2M$21.8M$42.7M-$-20.48M
Accounts receivable$30.2M-$-220K$3.41M$128.6M$5.23M
Inventory-$-4.12M$4.22M$15.2M$13.7M$30.7M
Accounts payable-$-14.22M-$-20.66M$2.83M-$-9.39M-$-10.85M
Net cash provided by operating activities-$-178.54M-$-183.49M-$-28.2M-$-95.19M$38.3M
Investments in property, plant and equipment-$-12.28M-$-25.01M-$-16.27M-$-24.58M-$-32.16M
Acquisitions, net$0.00$0.00-$-5M-$-1.76M-$-6M
Net cash used for investing activities$230.3M$352.2M-$-18.2M$91M$36M
Common stock issued-$-260K$0.00$0.00$0.00$0.00
Common stock repurchased-$-47.04M-$-90.22M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-118.06M$184.2M-$-11.3M$23M-$-10.35M
Net change in cash-$-62.87M$349.7M-$-57.31M$18.5M$62.5M
Cash at end of period$382.7M$445.6M$95.9M$153.2M$134.7M
Operating cash flow-$-178.54M-$-183.49M-$-28.2M-$-95.19M$38.3M
Capital expenditure-$-12.28M-$-25.01M-$-16.27M-$-24.58M-$-32.16M
Free cash flow-$-190.82M-$-208.5M-$-44.47M-$-119.77M$6.18M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About OPKO Health, Inc.

        OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.

        CEO
        Phillip Frost
        Employees
        2.28K
        Beta
        1.48

        Explore

        Frequently asked questions

        What is the intrinsic value of OPKO Health, Inc. (OPK)?

        OPKO Health, Inc. (OPK) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is OPK undervalued?

        OPK trades at a price of $1.57 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.